18 active not recruiting, 14 recruiting, 3 completed, 2 terminated. 21 Phase 2, 19 Phase 1, 3 Phase 3, 1 Early Phase 1, 1 Not applicable.
Follow Bone Marrow Aspiration and Biopsy: new trials by email Literature Review of Bone Marrow Aspiration and Biopsy trials Research Report on Bone Marrow Aspiration and Biopsy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial) Azacitidine, Bone Marrow Aspiration and Biopsy, Cytarabine - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 184 | 2027-01-04 | 2026-10-01 |
| Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia Eltanexor, Venetoclax, Bone Marrow Aspiration and Biopsy - Relapsed Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome | Phase 1 | Recruiting | Vanderbilt-Ingram Cancer Center | 60 | 2024-08-14 | 2026-08-19 |
| Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia Axatilimab, Azacitidine, Biospecimen Collection - Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia | Phase 1 / Phase 2 | Recruiting | Uma Borate | 49 | 2024-08-02 | 2026-08-27 |
| Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma Biopsy, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | OHSU Knight Cancer Institute | 40 | 2024-06-13 | 2026-07-07 |
| B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies Autologous BAFFR-targeting CAR T Cells, Bendamustine, Biopsy - B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Recruiting | Mayo Clinic | 27 | 2024-03-18 | 2026-02-13 |
| Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Cyclophosphamide - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Completed | Elvira Umyarova | 3 | 2024-03-05 | 2026-07-01 |
| SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Gilteritinib - Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With KMT2A Rearrangement | Phase 1 | Recruiting | Uma Borate | 30 | 2024-02-20 | 2026-05-14 |
| Tazemetostat and Palbociclib With CPX-351for R/R AML Tazemetostat, Liposome-encapsulated Daunorubicin-Cytarabine, Bone Marrow Aspiration and Biopsy - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Recruiting | Thomas Jefferson University | 24 | 2023-08-28 | 2026-03-12 |
| A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat Anti-CD123 ADC IMGN632, Bone Marrow Aspiration and Biopsy, Cytarabine - Recurrent Acute Myeloid Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Withdrawn | Children's Oncology Group | 2023-08-01 | 2023-09-01 | |
| CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission Autologous Anti-CD19 CAR-expressing T Lymphocytes, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - B Acute Lymphoblastic Leukemia | Phase 1 | Active not recruiting | City of Hope Medical Center | 18 | 2023-04-26 | 2026-10-08 |
| Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 165 | 2023-04-25 | 2026-10-13 |
| Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant Venetoclax, Decitabine, Cedazuridine - Recurrent Acute Myeloid Leukemia | Phase 2 | Terminated | Sanjay Mohan | 1 | 2023-04-13 | 2026-01-09 |
| Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Onvansertib - Recurrent Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia | Phase 1 | Recruiting | Mayo Clinic | 25 | 2023-04-04 | 2026-06-22 |
| Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Canakinumab - Clonal Cytopenia of Undetermined Significance | Phase 2 | Recruiting | Uma Borate | 110 | 2023-02-06 | 2026-01-02 |
| Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial Bone Marrow Aspiration and Biopsy, Carfilzomib, Computed Tomography - ISS Stage III Plasma Cell Myeloma, Multiple Myeloma | Phase 2 | Active not recruiting | Mayo Clinic | 17 | 2022-09-22 | 2026-05-13 |
| Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia Dasatinib, Methotrexate, Prednisone - B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 1 | Active not recruiting | OHSU Knight Cancer Institute | 20 | 2022-09-02 | 2026-05-06 |
| Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Liposome-encapsulated Daunorubicin-Cytarabine - Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 49 | 2022-08-24 | 2026-06-30 |
| Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Computed Tomography - Recurrent AL Amyloidosis, Refractory AL Amyloidosis | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 24 | 2022-08-03 | 2026-07-31 |
| Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies Anti-CD19/CD20/CD22 CAR T-Cells, Cyclophosphamide, Fludarabine Phosphate - Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | Sumithira Vasu | 54 | 2022-06-30 | 2026-05-29 |
| Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Cytarabine - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 5 | 2022-02-10 | 2026-10-06 |
Showing 20 of 40. Sign in to see all of them.
Leukemia, Myeloid, Acute (12) · Burkitt Lymphoma (8) · Lymphoma, Non-Hodgkin (6) · Leukemia, Myelomonocytic, Chronic (5) · Neuroblastoma (5) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Central Nervous System Neoplasms (4) · Ependymoma (4) · Glioma (4) · Hepatoblastoma (4) · Histiocytosis, Langerhans-Cell (4) · Leukemia, Biphenotypic, Acute (4) · Medulloblastoma (4) · Multiple Myeloma (4) · Myelodysplastic Syndromes (4)
National Cancer Institute (NCI) (15) · Children's Oncology Group (3) · Fred Hutchinson Cancer Center (3) · Mayo Clinic (3) · Uma Borate (3) · OHSU Knight Cancer Institute (2) · Thomas Jefferson University (2) · Alliance for Clinical Trials in Oncology (1) · City of Hope Medical Center (1) · Elvira Umyarova (1) · Istituto Giannina Gaslini (1) · Northwestern University (1) · Sanjay Mohan (1) · Sumithira Vasu (1) · Vanderbilt-Ingram Cancer Center (1)
United States (36) · Puerto Rico (8) · Canada (4) · Australia (2) · Israel (1) · Italy (1)
Uma M Borate, MD, MS (2) · Alice Lee (1) · Alvaro J Alencar (1) · Anjali S Advani (1) · Bayard Powell (1) · Brady Stein, MD (1) · Donald W Parsons (1) · Ehab L Atallah (1) · Elliot Stieglitz (1) · Elvira Umyarova, MD (1) · Gina Keiffer, MD (1) · Hans C Lee (1) · Ibrahim Aldoss (1) · Ivana Gojo (1) · Jessica T Leonard (1)
PMID 41671463, PMID 35622074, PMID 31401903, PMID 32589970, PMID 33591402, PMID 33728588, PMID 34028986, PMID 34486544, PMID 35007127, PMID 35353553, PMID 36322825, PMID 38867349, PMID 40226119, PMID 40685312, PMID 41166674, PMID 41796974, PMID 42341322, PMID 42686334
U10CA180886 (8), P30CA015704 (2), U10CA180820 (2), U10CA180821 (2), P01CA018029 (1), P01CA078902 (1), P30CA012197 (1), P30CA033572 (1), P30CA060553 (1), P50CA186781 (1), R01CA262287 (1), R01CA272496 (1), R01CA276374 (1), U10CA180868 (1), U10CA180888 (1)